Foreign Growth Helps Drive Boston Scientific's Q1 EPS Up 25%

Medical solutions provider Boston Scientific (NYSE: BSX  ) , known best for its myriad of cardiovascular and heart rhythm management products, on Tuesday reported modest but steady growth in the first quarter.

Revenue rose 1% year over year inclusive of negative currency effects to $1.77 billion. That rise was aided most by its MedSurg business division, which delivered a 7% increase in revenue to $548 million, and a 2% bump in its rhythm management division to $524 million. Within rhythm management, the company's neuromodulation segment saw sales improve 23% to $109 million. Revenue from its largest division, cardiovascular, fell fractionally to $700 million from $701 million in the prior-year period.

International sales were also a nice source of growth, with Boston Scientific noting that revenue rose 8% abroad, with emerging market sales up 22% for the quarter. Emerging-market revenue now accounts for 9% of total sales.

Adjusted earnings per share for the quarter improved 25% to $0.20, from $0.16 in the prior year. Helping boost profit was an absence of litigation expenses in the current quarter compared to last year, a 7% drop in the cost of products sold, a 6% dip in research and development costs, and the aforementioned improved sales. These lower costs were partially offset by a 6% increase in selling, general, and administrative costs tied to the launch of new products.

Looking ahead, Boston Scientific anticipates full-year revenue of $7.3 billion-$7.5 billion, representing currency-adjusted growth of 2%-5%. Furthermore, it slightly boosted its adjusted EPS guidance to a new range of $0.77-$0.82 from the previous projection of $0.75-$0.80. 

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2934906, ~/Articles/ArticleHandler.aspx, 9/1/2015 6:28:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 4:00 PM
BSX $16.74 Down -0.33 -1.93%
Boston Scientific… CAPS Rating: ***